5-p-tolyl-valeric acid amide | 860574-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-p-tolyl-valeric acid amide
• 英文别名: 5-p-Tolyl-valeriansaeure-amid；5-(4-Methylphenyl)pentanamide
• CAS: 860574-72-7
• 化学式: C₁₂H₁₇NO
• mdl: MFCD20545761
• 分子量: 191.273
• InChiKey: VJEDXZGJOJRLKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-p-tolyl-valeric acid amide 在 lithium aluminium tetrahydride 作用下， 生成 5-p-tolyl-pentylamine
  参考文献：
  名称：

  纤维蛋白稳定因子抑制剂。5.与单甲苯磺胺相关的伯胺。

  摘要：

  DOI：

  10.1021/jm00276a027
• 作为产物：
  描述：

  5-(氯甲基)二氢呋喃-2(3H)-酮 在 三氯化铝 作用下， 生成 5-p-tolyl-valeric acid amide
  参考文献：
  名称：

  Beyer, Chemische Berichte, 1937, vol. 70, p. 1482,1489

  摘要：

  DOI：

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS
  申请人：Haque Shamsul Tasir

  公开号：US20070238669A1

  公开（公告）日：2007-10-11

  The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified compounds that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The compounds of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

  本发明提供了新型人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于天然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或障碍。此外，本发明提供了新的化学修饰化合物，不仅可以刺激2型糖尿病患者的胰岛素分泌，还可以产生其他有益的胰岛素促进反应。这些合成肽GLP-1受体调节剂表现出对蛋白酶水解的稳定性增加，使它们成为口服或静脉注射理想的治疗候选药物。本发明的化合物在糖尿病疗效模型中表现出理想的药代动力学特性和理想的效力。
• METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS
  申请人：Moran Magdalene M.

  公开号：US20120046305A1

  公开（公告）日：2012-02-23

  Compounds and compositions for treating disorders related to TRPA1 are described herein.

  本文描述了用于治疗与TRPA1相关疾病的化合物和组合物。
• METHODS AND COMPOSITIONS FOR TREATING DISORDERS
  申请人：Ng Howard

  公开号：US20090143377A1

  公开（公告）日：2009-06-04

  Compounds and compositions for treating disorders related to TRPA1 are described herein.

  本文描述了用于治疗与TRPA1相关的疾病的化合物和组合物。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。